# A Systematic Review of Attributes Influencing Preferences for Treatments and Interventions in People With Amyotrophic Lateral Sclerosis (ALS)

## TL;DR

This study reviews what matters most to people with ALS when choosing treatments, highlighting factors like ease of use, autonomy, and safety to improve patient-centered care.

## Contribution

The study systematically synthesizes 44 preference-based studies to identify key factors influencing treatment preferences in ALS patients.

## Key findings

- Five key factors influencing preferences are ease of use, accessibility, autonomy, and safety/reliability.
- Preferences can inform healthcare policy and drug development through integration into target product profiles.
- Patient-centered care improves satisfaction and treatment effectiveness in ALS.

## Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that has no cure, and treatments predominantly focus on improving quality of life. Patient‐centred care is central to bringing about meaningful improvements to quality of life. This review addresses the lack of consolidated evidence on what matters most to people with ALS (pwALS) by synthesizing 44 preference‐based studies covering six different treatment and intervention categories. Data‐based convergent synthesis identified five overarching factors influencing preferences: ease of use, accessibility, making life easier, autonomy, and safety/reliability. Simplifying and enhancing accessibility of treatment delivery across disease stages aligns with the nature of neurodegenerative disorders such as ALS, where function declines as the disease progresses. The value in perceived and real control reflects the profound impact ALS has on an individual's independence. Safety and reliability are crucial for people with ALS and are recognized as fundamental requirements for quality healthcare. The themes identified in this review can inform the attributes of preference elicitation methods. Systematically varying the levels of these attributes elicits quantitative measures of preferences. These findings can be used to inform and develop healthcare policy and clinical practice in ALS care. Specifically, preferences related to drug treatments can then be integrated into target product profiles (TPPs) to align drug development with the needs and values of pwALS. Integrating patient preferences into clinical practice promotes patient‐centred care, increasing both patient satisfaction and treatment effectiveness.